EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia - Delgado - 2021 - The Oncologist - Wiley Online Library
Toby Eyre on Twitter: "Great news for #CLL pts in the UK that @AstraZeneca will provide #acalabrutinib for frontline patients during the #COVID19 era in an early access programme. Great to see
Public summary of opinion on orphan designation Acalabrutinib for the treatment of mantle cell lymphoma
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances | Leukemia
EX-EMPLOYEE v ASTRAZENECA
Molecules | Free Full-Text | PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
Evidence MIX (Measures, Insights, and eXamples): Evaluating the EU Regulatory System
EMA Recommends Granting a Marketing Authorisation
EMA Recommends 11 New Medicines For Approval Following July Meeting | HealthWire
acalabrutinib
Frontiers | Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
PDF) Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration
Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration
New Treatment Options in Oncology: FDA and EMA Drug Approvals in Q3 2022
Trends in kinase drug discovery: targets, indications and inhibitor design | Nature Reviews Drug Discovery
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies | Journal of Hematology & Oncology | Full Text
Calquence (acalabrutinib) - News, Articles etc. - European Pharmaceutical Review
Brand Institute, Inc - Congratulations to AstraZeneca on the EMA approval of CALQUENCE! #BIBrands CALQUENCE is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (
Lymphoma Hub on Twitter: "#SOHO2020 | Data on the second generation BTK inhibitor, acalabrutinib, in treatment-naive patients and R/R setting. #lymsm https://t.co/jXpoke8eWl" / Twitter
Frontiers | Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Schematic representation of a CLL cell with established and... | Download Scientific Diagram
What's new | European Medicines Agency
Michael Hallek on Twitter: "Following the presentations at the 2019 @ASH_hematology meeting and the recent approval of #venetoclax and #obinutuzumab by the European Medicines Agency, we have updated the 1L treatment algorithm
